AstraZeneca PLC (AZN)vsPetróleo Brasileiro S.A. - Petrobras (PBR-A)
AZN
AstraZeneca PLC
$182.85
+0.18%
HEALTHCARE · Cap: $286.68B
PBR-A
Petróleo Brasileiro S.A. - Petrobras
$18.67
-0.48%
ENERGY · Cap: $131.32B
Smart Verdict
WallStSmart Research — data-driven comparison
Petróleo Brasileiro S.A. - Petrobras generates 723% more annual revenue ($497.55B vs $60.44B). PBR-A leads profitability with a 22.1% profit margin vs 17.2%. AZN appears more attractively valued with a PEG of 1.52. PBR-A earns a higher WallStSmart Score of 67/100 (B-).
AZN
Buy62
out of 100
Grade: C+
PBR-A
Strong Buy67
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+6.6%
Fair Value
$220.34
Current Price
$182.85
$37.49 discount
Intrinsic value data unavailable for PBR-A.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 24 in profit
Strong operational efficiency at 28.2%
Generating 1.8B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Large-cap with strong market position
Every $100 of equity generates 28 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 26.9%
Areas to Watch
Expensive relative to growth rate
Moderate valuation
Distress zone — elevated risk
0.5% earnings growth
Expensive relative to growth rate
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 28.2%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : PBR-A
The strongest argument for PBR-A centers on P/E Ratio, Price/Book, Market Cap. Profitability is solid with margins at 22.1% and operating margin at 26.9%.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Altman Z-Score.
Bear Case : PBR-A
The primary concerns for PBR-A are EPS Growth, PEG Ratio, Altman Z-Score.
Key Dynamics to Monitor
AZN profiles as a mature stock while PBR-A is a value play — different risk/reward profiles.
AZN carries more volatility with a beta of 0.22 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
PBR-A generates stronger free cash flow (3.2B), providing more financial flexibility.
Bottom Line
PBR-A scores higher overall (67/100 vs 62/100), backed by strong 22.1% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Petróleo Brasileiro S.A. - Petrobras
ENERGY · OIL & GAS INTEGRATED · USA
Petrleo Brasileiro SA - Petrobras produces and sells oil and gas in Brazil and internationally. The company is headquartered in Rio de Janeiro, Brazil.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?